{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:18Z","timestamp":1789578318793,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.06.004","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:52:41Z","timestamp":1782503561000},"page":"938-945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy\u00a0\u00b1\u00a0Avelumab Maintenance for the Treatment of Locally Advanced\/Metastatic Urothelial Carcinoma"],"prefix":"10.1016","volume":"9","author":[{"given":"Ryan","family":"Dillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia N.","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"McLoone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen P.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence R.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.06.004_b0005","unstructured":"Astellas Pharma Incorporated, Seagen Inc. PADCEV\u00ae (enfortumab vedotin-ejfv) and KEYTRUDA\u00ae (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients with Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial; 2023. https:\/\/www.astellas.com\/en\/news\/28526."},{"key":"10.1016\/j.euo.2026.06.004_b0010","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.004_b0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.06.004_b0020","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.annonc.2025.05.536","article-title":"Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.004_b0025","unstructured":"Food and Drug Administration. Highlights of prescribing information: PADCEV. Revised 02\/2025; 2019. https:\/\/astellas.us\/docs\/PADCEV_label.pdf."},{"key":"10.1016\/j.euo.2026.06.004_b0030","unstructured":"European Medicines Agency. Padcev European public assessment report. Product number EMEA\/H\/C\/005392. Revised 17\/01\/2025; 2022, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/padcev."},{"key":"10.1016\/j.euo.2026.06.004_b0035","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.06.004_b0040","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.004_b0045","unstructured":"Food and Drug Administration. Highlights of prescribing information: BAVENCIO. Revised 06\/2025; 2017. https:\/\/www.emdserono.com\/us-en\/pi\/bavencio-pi.pdf."},{"key":"10.1016\/j.euo.2026.06.004_b0050","unstructured":"European Medicines Agency. Bavencio European public assessment report. Product number EMEA\/H\/C\/004338. Revised 07\/05\/2025; 2017, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bavencio."},{"key":"10.1016\/j.euo.2026.06.004_b0055","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.euo.2026.06.004_b0060","series-title":"NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE","author":"Phillippo","year":"2016"},{"issue":"6","key":"10.1016\/j.euo.2026.06.004_b0065","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jval.2024.03.224","article-title":"CO137 Are standard indirect treatment comparison methods suitable to compare first-line vs maintenance therapies? An assessment of enfortumab vedotin\u00a0+\u00a0Pembrolizumab vs Avelumab in locally advanced\/metastatic urothelial carcinoma","volume":"27","author":"Dillon","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.euo.2026.06.004_b0070","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): bladder cancer. version 1.2025; 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"10.1016\/j.euo.2026.06.004_b0075","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.004_b0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euo.2026.06.004_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102248","article-title":"Outcomes by retrospective eligibility for maintenance therapy of patients with advanced urothelial carcinoma: post hoc analysis of the Phase 3 KEYNOTE-361 trial","volume":"23","author":"Mamtani","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.06.004_b0090","unstructured":"Astellas Pharma Incorporated European Commission. Approves Astellas\u2019 PADCEV (enfortumab vedotin) in Combination with KEYTRUDA (pembrolizumab) for First-Line Treatment of Advanced urothelial Cancer; 2024, https:\/\/www.astellas.com\/en\/news\/29371."},{"key":"10.1016\/j.euo.2026.06.004_b0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/fon-2022-0767","article-title":"Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients","volume":"19","author":"Grivas","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2026.06.004_b0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.euo.2024.09.014","article-title":"Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment","volume":"8","author":"Barth\u00e9l\u00e9my","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.06.004_b0105","doi-asserted-by":"crossref","first-page":"594.e19","DOI":"10.1016\/j.urolonc.2025.05.014","article-title":"Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy","volume":"43","author":"Moon","year":"2025","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"10.1016\/j.euo.2026.06.004_b0110","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.3390\/curroncol31080352","article-title":"Immunotherapy-based combinations in first-line urothelial cancer: A systematic review and individual patient data (IPD) meta-analysis","volume":"31","author":"Di Civita","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.euo.2026.06.004_b0115","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/CLEP.S409791","article-title":"Benchmarking maintenance therapy survival in first-line platinum-based chemotherapy-treated patients with advanced urothelial carcinoma using simulated disease modeling","volume":"15","author":"Galsky","year":"2023","journal-title":"Clin Epidemiol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:47:31Z","timestamp":1789577251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126001720"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.06.004","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy\u00a0\u00b1\u00a0Avelumab Maintenance for the Treatment of Locally Advanced\/Metastatic Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}